# Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Source: https://onco.cc/trials/nct04655976/  
OnCo record `nct04655976` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing Cobolimab in non-small-cell lung cancer, active and no longer recruiting.

## Summary

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy is a phase 2/3 interventional study registered as NCT04655976, led by GlaxoSmithKline, and active but no longer recruiting on the registry. Official title: A Randomised, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung). Planned enrolment is 758 participants (actual). The study started in 2020-12-08 and primary completion is expected in 2025-06-05. Results have been posted on ClinicalTrials.gov; they are not yet summarised here.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: COSTAR Lung
- Tags: ctgov-ingest
- Registry id: NCT04655976
- Phase: 2/3
- Setting: A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
- Sponsor: GlaxoSmithKline
- Enrolled: 758
- Outcomes: Overall Survival (OS) (Arm A Versus Arm C): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 months vs Docetaxel (Arm C) 11.3 months, HR 0.85; Overall Survival (OS) (Arm B Versus Arm C): Dostarlimab + Docetaxel (Arm B) 11.8 months vs Docetaxel (Arm C) 11.3 months, HR 0.96; Progression Free Survival (PFS): Cobolimab + Dostarlimab + Docetaxel (Arm A) 4.4 months vs Dostarlimab + Docetaxel (Arm B) 4.2 months vs Docetaxel (Arm C) 4.1 months; Overall Response Rate (ORR): Cobolimab + Dostarlimab + Docetaxel (Arm A) 18.7% vs Dostarlimab + Docetaxel (Arm B) 18.3% vs Docetaxel (Arm C) 14.5%

## Sources

- ClinicalTrials.gov NCT04655976: https://clinicaltrials.gov/study/NCT04655976

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [TIM-3 blockade](https://onco.cc/technologies/tim3-blockade/)
- drugs: [Cobolimab](https://onco.cc/drugs/cobolimab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct04655976.json